Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease
NCT06674460Phase 3Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke and Cerebral Small Vessel Disease (CSVD) comparing Edaravone Dexborneol Sublingual Tablets with Placebo (2 arms). Primary endpoint: Hierarchical Composite Endpoint at 24 weeks. Started Aug 2025; status: recruiting.
02
Drugs
edaravonedexborneol
03
Conditions
ischemic strokeCerebral Small Vessel Disease (CSVD)
Beyond the preview
Go deeper on NCT06674460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06674460.